A trial of dextromethorphan in parkinsonian patients with motor response complications

Movement Disorders

Volumn 13, Issue 3, 1998, Pages 414-417

  Metman, Leo Verhagen ^a   Blanchet, Pierre J ^a   Van Den Munckhof, Pepÿn ^a   Del Dotto, Paolo ^a   Natté, Remco ^a   Chase, Thomas N ^a,b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

Glutamate; Motor complications; NMDA

Indexed keywords

DEXTROMETHORPHAN; LEVODOPA; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DYSKINESIA; FEMALE; HUMAN; IMPOTENCE; MALE; MOTOR DYSFUNCTION; NAUSEA; PARKINSON DISEASE; PRIORITY JOURNAL; RATING SCALE;

ACTIVITIES OF DAILY LIVING; AGED; ANTIPARKINSON AGENTS; CARBIDOPA; CROSS-OVER STUDIES; DEXTROMETHORPHAN; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; MALE; MIDDLE AGED; MOTOR SKILLS; N-METHYLASPARTATE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE;

EID: 0031945065     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/mds.870130307     Document Type: Article

References (21)

1. Marsden C. Problems with long-term levodopa therapy for Parkinson's disease. Clin Neuropharmacol 1994;17(suppl 2):S32-S44.
2. Bravi D, Mouradian MM, Roberts JW, Davis TL, Sohn YH, Chase TN. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31.
3. Colosimo C, Merello M, Hughes AJ, Sieradzan K, Lees AJ. Motor response to acute dopaminergic challenge with apomorphine and levodopa in Parkinson's disease: implications for the pathogenesis of the on-off phenomenon. J Neurol Neurosurg Psychiatry 1996; 60:634-637.
4. Verhagen Metman L, Locatelli ER, Bravi D, Mouradian MM, Chase TN. Apomorphine responses in Parkinson's disease and the pathogenesis of motor complications. Neurology 1997;48:369-372.
5. Chase TN, Engber TM, Mouradian MM. Contribution of dopaminergic and glutamatergic mechanisms to the pathogenesis of motor response complications in Parkinson's disease. Adv Neurol 1996; 69:497-501.
6. Engber TM, Papa SM, Boldry RC, Chase TN. NMDA receptor blockade reverses motor response alterations induced by levodopa. Neuroreport 1994;5:2586-2588.
7. Papa SM, Boldry RC, Engber TM, Kask AM, Chase TN. Reversal of levodopa-induced motor fluctuations in experimental parkinsonism by NMDA receptor blockade. Brain Res 1995;701:13-18.
8. Papa SM, Chase TN. Levodopa induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996; 39:574-578.
9. Blanchel PJ, Verhagen Metman L, Mouradian MM, Chase TN. Acute pharmacologic blockade of dyskinesias in Parkinson's disease. Mov Disord 1996;11:580-581.
10. Wong BY, Coulter DA, Choi DW, Prince DA. Dextrorphan and dextromethorphan, common antitussives, are antiepileptic and antagonize N-methyl-D-aspartate in brain slices. Neurosci Lett 1988; 85:261-266.
11. Church J, Jones MG, Davies SN, Lodge D. Antitussive agents as N-methylaspartate antagonists: further studies. Can J Physiol Pharmacol 1989;67:561-567.
12. Zhang Y, Britto MR, Valderhaug KL, Wedlund PJ, Smith RA. Dextromethorphan: enhancing its systemic availability by way of low-dose quinidine-mediated inhibition of cytochrome P4502D6. Clin Pharmacol Ther 1992;51:647-655.
13. Davis TL, Brughitta G, Baronti F, Mouradian MM. Acute effects of pulsatile levodopa administration on central dopamine pharmacodynamics. Neurology 1991;41:630-633.
14. Herrling PL, ed. Excitatory Amino Acids: Clinical Results with Antagonists. San Diego, CA: Academic Press, 1997.
15. Bonuccelli U, Del Dotto P, Piccini P, Beghé F, Corsini GU, Muratorio A. Dextromethorphan and parkinsonism [Letter]. Lancet 1992;340:53.
16. Montastruc JL, Fabre N, Rascol O, Senard JM, Blin O. N-methyl-D-aspartate (NMDA) antagonist and Parkinson's disease: a pilot study with dextromethorphan. Mov Disord 1994;9:242-243.
17. Tortella FC, Pellicano M, Bowery NG. Dextromethorphan and neuromodulation: old drug coughs up new activities. Trends Pharmacol Sci 1989;10:501-507.
18. Goldstein SR, Matsumoto RR, Thompson TL, Patrick RL, Bowen WD, Walker JM. Motor effects of two sigma ligands mediated by nigrostriatal dopamine neurons. Synapse 1989;4:254-258.
19. Debonnel G, De Montigny C. Modulation of NMDA and dopaminergic neurotransmissions by sigma ligands: possible implications for the treatment of psychiatric disorders. Life Sci 1996;58:721-734.
20. Kotter R. Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum. Prog Neurobiol 1994;44:163-196.
21. Greenamyre JT. Pharmacological pallidotomy with glutamate antagonists. Ann Neurol 1996;39:557-558.